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Background: Reirradiation using brachytherapy (BT) and external beam radiation therapy
(EBRT) are salvage strategies with locally radiorecurrent prostate cancer. This systematic
review describes the oncologic and toxicity outcomes for salvage BT and EBRT [including
Stereotactic Body Radiation Therapy (SBRT)].
Methods: An International Prospective Register of Systematic Reviews (PROSPERO)
registered (#211875) study was conducted using Preferred Reporting Items for
Systematic reviews and Meta-analyses (PRISMA) guidelines. EMBASE and MEDLINE
databases were searched from inception to December 2020. For BT, both low dose rate
(LDR) and high dose rate (HDR) BT techniques were included. Two authors independently
assessed study quality using the 18-item Modified Delphi technique.
Results: A total of 39 eligible studies comprising 1967 patients were included (28 BT and
11 SBRT). In 35 studies (90%), the design was single centre and/or retrospective and no
randomised prospective studies were found. Twelve BT studies used LDR only, 11 HDR
only, 4 LDR or HDR and 1 pulsed-dose rate only. All EBRT studies used SBRT exclusively,
four with Cyberknife alone and 7 using both Cyberknife and conventional linear accelerator
treatments. Median (range) modified Delphi quality score was 15 (6-18). Median (range)
follow-up was 47.5 months (13-108) (BT) and 25.4 months (21-44) (SBRT). For the LDR-BT
studies, the median (range) 2-year and 5-year bRFS rates were 71% (48-89.5) and 52.5%
(20-79). For the HDR-BT studies, the median (range) 2-year and 5-year bRFS rates were
74% (63-89) and 51% (45-65). For the SBRT studies, the median (range) 2-year bRFS for
the SBRT group was 54.9% (40-80). Mean (range) acute and late grade≥3 GU toxicity rates
for LDR-BT/HDR-BT/SBRT were 7.4%(0-14)/2%(0-14)/2.7%(0-8.7) and 13.6%(0-30)/
7.9%(0-21.3%)/2.7%(0-8%). Mean (range) acute and late grade≥3 GI toxicity rates for
LDR-BT/HDR-BT/SBRT were 6.5%(0-19)/0%/0.5%(0-4%) and 6.4%(0-20)/0.1%(0-0.9)/
0.2%(0-1.5). One third of studies included Patient Reported Outcome Measures (PROMs).
Conclusions: Salvage reirradiation of radiorecurrent prostate cancer using HDR-BT or
SBRT provides similar biochemical control and acceptable late toxicity. Salvage LDR-BTSeptember 2021 | Volume 11 | Article 6814481
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Frontiers in Oncology | www.frontiersin.orgis associated with higher late GU/GI toxicity. Challenges exist in comparing BT and SBRT
from inconsistencies in reporting with missing data, and prospective randomised trials
are needed.Keywords: prostate cancer, local recurrence, reirradiation, salvage, brachytherapy, external beam radiotherapy
(EBRT), stereotactic body radiotherapy (SBRT)INTRODUCTION
Prostate cancer is the most common male cancer accounting for
over 1.2 million new cases per year with >350,000 deaths (3.8% of
all male cancer deaths) (1). Radiation therapy (RT) is a curative
treatment option for localised prostate cancer and can be offered
to patients from all risk groups (2). Despite advances in
diagnostic imaging, RT delivery techniques and dose-escalated
radiation, biochemical progression remains common and occurs
in 15–57% of patients with localised disease (3–5).
Multiple salvage options are available for locally recurrent
non-metastatic disease including prostatectomy, reirradiation
[with brachytherapy (BT) or external beam radiotherapy
(EBRT)] and other focal therapies such as high-intensity
focused ultrasound (HIFU) and cryotherapy. However, there is
limited evidence to support the effectiveness of salvage therapies
with concerns regarding the potential for significant toxicity that
may impact the long-term quality of life of patients. Due to
uncertainty regarding benefits and risks of harm only 15-20%of
patients with locally recurrent prostate cancer undergo salvage
therapy according to the Cancer of the Prostate Strategic
Urologic Research Endeavor (CaPSURE) registry (6).
BT has been preferred for reirradiation as it offers delivery of
highly conformal high dose radiation with a steep dose gradient
and rapid fall off which minimises dose to surrounding organs at
risk (7). Disadvantages of BT include its invasive nature and the
need for a specialist multi-disciplinary team not available in all
radiation centres. Previously, EBRT techniques have been
associated with high rates of severe late toxicities and poor
local control (8). Stereotactic body radiation therapy (SBRT)
involves delivery of a high dose of external beam radiation to a
highly conformal target volume with a steep dose gradient in a
small number of fractions and is now under investigation for
locally recurrent prostate cancer. Advantages of this approach
are that it is non-invasive and has the potential to be delivered in
more radiation centres than BT (9).
This systematic review collates the most up-to-date evidence
for reirradiation of locally recurrent prostate cancer. Two
previous systematic reviews which compared all salvage
therapies found higher biochemical control rates for BT and
EBRT compared to surgical and other non-surgical local
therapies [high intensity focused ultrasound (HIFU) and
cryotherapy] along with potentially lower genitourinary (GU)
toxicity (10, 11). The justification for this systematic review is
that the identification of the reirradiation modality that offers
optimum prostate cancer control and minimal toxicity is
important to enable patients to make informed decisions and
potentially improve outcomes in patients with radiorecurrent2
prostate cancer. In addition, the evidence base for salvage BT and
SBRT continues to expand with a number of new publications in
the past 1-2 years.METHODS AND MATERIALS
An International Prospective Register of Systematic Reviews
registered (#211875) systematic review was conducted.
Study Design
The study followed the Preferred Reporting Items for Systematic
Reviews and Meta-analysis (PRISMA) guidelines (12).
Studies were identified by searching the Cochrane library,
EMBASE and MEDLINE electronic databases from inception to
14th December 2020.
The search strategy is documented inSupplementaryMaterial 1
and the combination of subject headings and keywords included:
‘recurrent or radiorecurrent prostate cancer’, ‘reirradiation’ or ‘re-
irradiation’, ‘salvage radiotherapy’, ‘brachytherapy’, ‘external beam
radiotherapy’, ‘stereotactic body radiation therapy’, ‘stereotactic
ablative radiotherapy’, ‘radiosurgery’.
Data Extraction
Two authors (JZ and FS) independently reviewed the abstracts
and assessed the quality of each study using an 18-item Modified
Delphi technique, which has been previously validated for case
series (13). Discordance between reviewers were resolved
following arbitration by a third reviewer (AH).
Data Selection
Eligible studies included patients treated with primary EBRT, BT
or combination EBRT/BT and salvage therapy for local
recurrence with either EBRT or BT. For BT techniques, studies
of high-dose rate brachytherapy (HDR-BT), low-dose rate
brachytherapy (LDR-BT) and pulse-dose rate brachytherapy
(PDR-BT) were included.
Studies that predominantly included patients who had
primary treatment with radical prostatectomy, cryotherapy or
HIFU were not included in this review as the focus was to collate
and present the most up-to-date evidence concerning
reirradiation specifically.
Studies with fewer than 20 patients were excluded, along with
editorials, letters, abstracts, case reports, conference proceedings
and studies not written in English. Where studies had evaluated
the same patient cohort as another publication, only the most
recent publication was used for analysis unless distinct treatment
outcomes or toxicity were described.September 2021 | Volume 11 | Article 681448
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Extracted data included the first author and country in which the
study took place, study type (prospective or retrospective), single/
multi-centre status, number of patients, primary disease
characteristics, primary treatment modalities, interval between
original treatment and salvage treatment, patient age at salvage,
pre-salvage prostate specific antigen (PSA), diagnostic imaging
prior to salvage treatment, histological confirmation of local
recurrence and percentage of biopsy-proven recurrences in
study cohort, whole-gland salvage treatment versus focal salvage
treatment, type of salvage radiotherapy (HDR-BT, LDR-BT, PDR-
BT or EBRT), salvage dose fractionation schedule, percent of
patients who received androgen deprivation therapy (ADT) with
their salvage treatment, duration of follow up post salvage therapy,
treatment outcomes [biochemical control (BC), biochemical
recurrence free survival (bRFS), metastasis free survival (MFS),Frontiers in Oncology | www.frontiersin.org 3relapse free survival (RFS), cancer specific survival (CSS), overall
survival (OS)] and grade 1-4 GU and gastrointestinal (GI) toxicity
as classified by the Common Terminology Criteria for Adverse
Events (CTCAE) (14) or Radiation Therapy Oncology Group
(RTOG) score (15). Use of any patient recorded outcome measure
(PROM) in the study was also collated including the type of tool
used. Median (range) values calculated for all collected variables
except toxicity rates where mean (range) used to account for the
studies which report no toxicity.RESULTS
From the initial identification of 2744 articles, a total of 39 studies
were included in the final analysis. A PRISMA flowchart of the
systematic review is presented in Figure 1. The last electronic
literature search was performed on 14th December 2020.FIGURE 1 | PRISMA flow chart of literature search.September 2021 | Volume 11 | Article 681448
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checklist) scores for all included studies are shown in
Supplementary Table 1. The summary of these results is
shown in Table 1. The median modified Delphi score was 15
out of 18 (83.3%) (range 6-18).
Treatment Details
A summary of patient, disease and treatment characteristics at
the time of primary treatment and salvage treatments for BT and
EBRT studies is shown in Tables 2–5 respectively. Salvage
treatment characteristics for BT and EBRT are shown in
Tables 6, 7 respectively.
Twenty-eight BT studies were included with a total of 1484
patients treated: 22 were retrospective and 6 were prospective.
Four were multi-centre and 24 were single centre. Twelve BT
studies used LDR only (16–27), 11 used HDR only (28–39), 4
used LDR or HDR (40–43) and 1 used PDR only (44). Twenty
four studies used whole gland salvage treatments and 4 studies
used focal salvage treatments (16, 34, 36, 38). The number of
HDR-BT fractions ranged from 1 to 4 (median of 3 fractions)
and the inter-fraction time interval ranged from 4 hours to 3
weeks. The median overall salvage treatment time was 21 days
(range 1 to 63 days).
All EBRT studies (n=11) used an SBRT technique with a total
of 483 patients treated. Of these studies (9, 45–54), 9 were
retrospective and 2 were prospective (46, 47). Two were multi-
centre and 9 were single centre. Four studies used Cyberknife
delivery only and 7 studies included patients treated withFrontiers in Oncology | www.frontiersin.org 4Cyberknife or conventional linear accelerator SBRT techniques.
Four studies used whole gland salvage only, 4 focal salvage only,
2 included both whole gland and focal treatments and one did
not specify. Of the 11 studies, 8 were published between 2019 and
2020. The median total radiation dose prescribed was 34 Gy
(range 34-38 Gy), over a median of 5 fractions (range 3-7). The
median overall treatment time was 6 days (range 3-14 days).
The median number (range) of included patients for
individual BT and SBRT studies was 44 (21-115) and 42 (23-
100) respectively. The median age (range) at salvage treatment
was 70 years (59-76) for BT studies and 74 years (64-78) for
SBRT studies. The median PSA at primary treatment for the BT
and SBRT studies were 10.9 ng/mL (range 7.4-26.4) and 10.3 ng/
mL (range 8.7-13.0) respectively. The median PSA at salvage
treatment for the BT and SBRT studies were 4.7 ng/mL (range
2.8-11.4) and 3.1 ng/mL (range 2.5-4.1) respectively. The median
time from primary treatment to salvage therapy for the BT and
SBRT studies were 67 months (range 30-101 months) and 86.5
months (range 60-100 months) respectively.
Seventeen studies (44%) used both multi-parametric
magnetic resonance imaging (mpMRI) and positron emission
tomography-computed tomography (PET-CT) for restaging
prior to salvage treatment. Four studies (10%) used prostate-
specific membrane antigen (PSMA) PET-CT and 13 studies
(33%) used choline/fluciclovine PET-CT for re-staging. Eight
studies (all BT) (21%) used computed tomography (CT) or
isotope bone scintigraphy for restaging. Ten studies (26%) did
not report the imaging modality used for restaging. Among theTABLE 1 | Summary findings from the Modified Delphi checklist for quality assessment applied to all included studies (n=39).
Criterion Studies, n (%)
Yes No
Study Objective
1. Is the hypothesis/aim/objective of the study clearly stated in the abstract, introduction, or methods section? 38 (97.4) 1 (2.6)
Study population
2. Are the characteristics of the participants included in the study described? 100 (100) 0 (0)
3. Were the cases collected in more than 1 Centre? 8 (20.5) 31 (79.5)
4. Are the eligibility criteria (inclusion and exclusion criteria) to entry the study explicit and appropriate? 33 (84.6) 6 (15.4)
5. Were the participants recruited consecutively? 26 (66.7) 13 (33.3)
6. Did participants enter the study at a similar point in the disease? 35 (89.7) 4 (10.3)
Intervention and co-intervention
7. Was the intervention clearly described in the study? 37 (94.9) 2 (5.1)
8. Were additional interventions (co-interventions) clearly reported in the study? 35 (89.7) 4 (10.3)
Outcome measures
9. Are the outcome measures clearly defined in the introduction or methods section? 38 (97.4) 1 (2.6)
10. Were relevant outcomes appropriately measured with objective/or subjective methods? 38 (97.4) 1 (2.6)
11. Were outcomes measured before and after intervention? 35 (89.7) 4 (10.3)
Statistical analysis
12. Were the statistical tests used to assess the relevant outcomes appropriate? 38 (97.4) 1 (2.6)
Results and conclusions
13. Was the length of follow-up reported? 38 (97.4) 1 (2.6)
14. Was the loss of follow-up reported? 23 (59.0) 16 (41.0)
15. Does the study provide estimates of the random variability in the data analysis of relevant outcomes? 15 (38.5) 24 (61.5)
16. Are adverse events reported? 38 (97.4) 1 (2.6)
17. Are the conclusions of the study supported by results? 38 (97.4) 1 (2.6)
Competing interest and source of support
18. Are both competing interest and source of support for the study reported? 23 (59.0) 16 (41.0)
Median Modified Delphi score = 15 out of 18 (83.3%) (range 6-18)September 2021 | Volume 11 | Article 681448





Risk Class Primary treatment
48 52 NR EBRT, BT, protonTx
58 42 NR RP+EBRT, EBRT, BT,
EBRT+BT
NR NR NR EBRT, BT, EBRT+BT, PBT
48 52 Intermediate EBRT
NR NR NR EBRT
NR NR High EBRT, EBRT+BT
NR NR Low BT, EBRT+BT
NR NR Intermediate EBRT, EBRT+BT
NR NR Intermediate EBRT, BT
NR NR Intermediate EBRT
72 28 Intermediate EBRT, BT
73% 27% Intermediate EBRT, BT
72 28 NR EBRT, BT
68 32 NR EBRT, BT, EBRT+BT
55 45 High EBRT
87 13 Intermediate EBRT, BT
NR NR NR EBRT, BT, RP
32% 68% NR BT
NR NR NR EBRT, EBRT+BT
NR NR NR EBRT
NR NR NR EBRT
19 16 Intermediate EBRT, BT
NR NR NR EBRT, BT
NR NR High EBRT, BT
NR NR NR EBRT




67 5 Intermediate EBRT
NR NR Intermediate EBRT, BT, RP
tigen; NR, not recorded; GS, Gleason score; EBRT, external beam radiotherapy; PBT, proton

















































B Lee (USA) 2007 HDR R 21 NR 1 6 100 0 T2c
Lyczek (Poland) 2009 HDR R 115 13 (2.34-64.5) NR NR NR NR T2
Chen (USA) 2013 HDR R 52 9.3 (1.2-58) 1 6 87 13 T2
Kukielka (Poland) 2014 HDR R 25 16.3 (6.37-64) 1 <6 88 4 T2c
*Yamada (USA) 2014 HDR P 42 NR NR NR NR NR NR
Jiang (Germany) 2016 HDR R 29 NR NR NR NR NR NR
Lacy (USA) 2016 HDR R 21 NR NR NR NR NR NR
Wojcieszek (Poland) 2016 HDR R 83 13.7 1 6 80 4 T2
Lopez (Spain) 2019 HDR R 75 8.9 (3.5-42.1) 1 6 75 20 NR
2019 LDR R 44 14.2 (3.2-167) 1 6 87 11 NR
Chitmanee (UK) 2020 HDR P 50 <10 (46%) 2/3 7 90 10 T2
Slevin (UK) 2020 HDR R 43 10.5 (3.4-178) 1 6 90 10 T2
van Son
(Netherlands)
2020 HDR P 50 13 (2.1-140) 1 6 82 12 T2a
Kollmeier (USA) 2017 HDR/LDR R 98 ≤10 (74%) 2 7 92 8 T2b
Baumann (USA) 2017 HDR/LDR R 33 8.4 (3.8-68.7) NR 7 79 21 T2
Henriquez (Spain) 2014 HDR/LDR R 56 10.7 (4-121) 1 6 95 5 T2
Grado (USA) 1999 LDR R 49 26.4 (2.3-95.8) NR 7 to
10
NR NR T2b
Koutrouvelis (USA) 2003 LDR R 31 <10 (32%) NR 6 77 23 T2b/
T3a
Nguyen (USA) 2007 LDR P 25 7.4 (4.2-18.4) 1 6 100 0 T1c
HK Lee (USA) 2008 LDR R 21 NR NR NR NR NR NR
Aaronson (USA) 2009 LDR R 24 9.9 (3.2-69) 3 7 71 12 T1c
Burri (USA) 2010 LDR R 37 10.9 (4.4-81) NR 6 73 11 NR
Moman
(Netherlands)
2010 LDR R 31 24.3 NR 7 84 6.5 T2
Peters (Netherlands) 2014 LDR R 20 12.9 (5.4-51) 1 6 90 10 T3
Vargas (USA) 2014 LDR R 69 <10 (62%) 1 6 80.3 19.7 T2
Peters (Netherlands) 2016 LDR R 62 16.6 (2.6-66.9) 2/3 7 95 5 T2
Crook (Canada) 2019 LDR P 92 NR NR 7 100 0 NR
Smith (USA) 2020 LDR P 108 9.15 (1.7-116) 1 6 54 10 T2
Schonle (Germany) 2020 PDR R 82 9 (0.9-170) 2/3 7 74 11 NR
BT, brachytherapy; HDR, high dose rate; LDR, low dose rate; R, retrospective; P, prospective; Pts, patients, n, nnumber; PSA, prostate specific an
beam treatment; RP, radical prostatectomy.
For PSA, ISUP and GS, the median scores are presented.
*Yamada (USA) study cohort included in further publication Kollmeier (USA) however specific treatment characteristics and toxicity were not cov
TABLE 3 | Pre-salvage therapy disease and treatment characteristics for brachytherapy studies.
A (ng/mL)(range) ISUP GS % GS (≤7) % GS (≥8) Imaging for relapse Biopsy
5.9 (1.4-9.5) NR NR 52 38 MRI Yes (100%)
NR 1 6 71 12 NR No
5 (0.4-26.3) NR 8 48 52 CT Yes (100%)
2.8 (1.04-25.3) 2/3 7 60 20 MRI Yes (100%)
3.54 NR 7 67 33 MRI, BS Yes (100%)
4.05 (2.1-18.6) NR NR NR NR C-PET No
6.3 (1-19.1) NR NR NR NR CT, BS Yes (14%)
3.1 (0.1-19.9) NR 7 46 7 MRI, BS Yes (100%)
4.1 (1.5-16.7) NR 8 to 10 48 44 CT, MRI,
C-PET
Yes (100%)
3.6 (1.02-11) 2/3 7 59 9 CT, MRI,
C-PET
Yes (100%)
<10 (94%) 2/3 7 54 36 MRI, C-PET Yes (100%)
3.1 (1.1-7.5) 2 7 70 30 MRI, PET Yes (100%)
5 (0.9-39) 2 7 74 20 PSMA-PET, MRI Yes (100%)
3.7 (0-59) 2 7 61 39 CT, MRI, BS Yes (100%)
5 (2-26) NR 7 55 36 CT, MRI, BS Yes (100%)
3.7 (1.1-30) 2/3 7 41 14 MRI Yes (100%)
5.6 (1.5-79.1) NR NR NR NR CT Yes (100%)
NR NR 6 NR NR NR Yes (100%)
5.5 (1.4-11.6) NR NR NR NR MRI Yes (100%)
3.8 NR 7 NR NR NR Yes (100%)
3.41 (0.3-10) NR NR NR NR MRI Yes (100%)
5.6 (1.7-35) NR 8 65 32 CT Yes (100%)
11.4 NR 8 70.1 12.9 NR Yes (100%)
4.7 (0.3-14) NR 7 65 35 MRI, CT/BS, C-PET Yes (100%)
NR NR 7 73.2 26.8 CT, BS Yes (100%)
8.6 (0.1-92.6) NR NR NR NR MRI, PET, BS Yes (100%)
4.1 (0.4-9.7) NR NR NR NR MRI Yes (100%)
5.3 (0.1-38.4) 3 7 65 32 MRI Yes (100%)
5.07 (0.28-51) 2/3 7 59 24 MRI NR
re; TRS, median time from primary treatment to salvage therapy; mo, months; BCR, biochemical recurrence;
y; US, ultrasound; C-PET, Choline positron emission tomography; PSMA, prostate specific membrane antigen.



































First author (country) Year Salvage BT type TRS (mo)(range) BCR definition Age (years)(range) P
B Lee (USA) 2007 HDR 63.6 (24-125) NR 68 (58-81)
Lyczek (Poland) 2009 HDR 49.5 NR 70 (52-82)
Chen (USA) 2013 HDR 51.6 (10.8-135.6 Phoenix 67.5 (53.9-81.4)
Kukielka (Poland) 2014 HDR NR Phoenix 71 (62-83)
*Yamada (USA) 2014 HDR 73 Phoenix 72
Jiang (Germany) 2016 HDR NR Phoenix 75.5 (±5.8)
Lacy (USA) 2016 HDR 45 (4-287) Phoenix 59 (44-72)
Wojcieszek (Poland) 2016 HDR 67 (22-124) NR 70 (57-81)
Lopez (Spain) 2019 HDR > 30 ASTRO/ Phoenix 62.1 (4-75)
2019 LDR > 30 ASTRO/ Phoenix 60.4 (47-71)
Chitmanee (UK) 2020 HDR < 5 years Phoenix 70 (57-82)
Slevin (UK) 2020 HDR 70 Phoenix 70 (62-81)
van Son (Netherlands) 2020 HDR 101 (25-228) Phoenix 71 (59-83)
Kollmeier (USA) 2017 HDR/LDR 72 (12-172) Phoenix 73.5 (56-88)
Baumann (USA) 2017 HDR/LDR 56.1 (18-118) Phoenix 75 (57-85)
Henriquez (Spain) 2014 HDR/LDR NR Phoenix 65 (60-80)
Grado (USA) 1999 LDR NR 2 PSA rises>nadir 73.3 (52.9-86.9)
Koutrouvelis (USA) 2003 LDR 30 nPSA+1.5 65 (51-79)
Nguyen (USA) 2007 LDR 62.4 (30-153) ASTRO 65
HK Lee (USA) 2008 LDR 85 (±30.1) Phoenix 72 (±4.8)
Aaronson (USA) 2009 LDR 49 (26-109) Phoenix 66 (54-88)
Burri (USA) 2010 LDR 62 (26-171) Phoenix 70.2 (51-79)
Moman (Netherlands) 2010 LDR 60 ASTRO/ Phoenix 69.3
Peters (Netherlands) 2014 LDR 79 (42-144) Phoenix 69 (59-78)
Vargas (USA) 2014 LDR 90 Phoenix 72.5 (55-88)
Peters (Netherlands) 2016 LDR 67 (±32) Phoenix 69 (±5.3)
Crook (Canada) 2019 LDR 85 (39-199) Phoenix 70 (55-82)
Smith (USA) 2020 LDR 70 (10-235) Phoenix 70 (51-87)
Schonle (Germany) 2020 PDR 87.5 (19-255) Phoenix 69.9 (51-83)
BT, brachytherapy; HDR, high dose rate; LDR, low dose rate; PSA, prostate specific antigen; NR, not recorded; GS, Gleason sc
ASTRO, American Society for Radiation Oncology; MRI, magnetic resonance imaging; NS, bone scan; CT, computed tomograph
For TRS, age, PSA, ISUP and GS, the median scores are presented.
*Yamada (USA) study cohort included in further publication Kollmeier (USA) however specific treatment characteristics and toxS
o
i
TABLE 4 | Primary disease and treatment characteristics for EBRT studies.
) PSA (range) (ng/mL) T stage (≤T2a) % T stage (≥T2b) Risk Class Primary treatment
10.38 (2.34-57) 65.2 30.4 NR EBRT, BT
NR NR NR NR EBRT, BT, RP
11.4 (0.5-228.5) NR NR NR EBRT, BT
10 (3.1-160) NR NR High EBRT, RP+EBRT
NR NR NR Intermediate RP+EBRT, EBRT
10.2 (2.3-120) NR NR Intermediate EBRT
10.1 (3-120) NR NR Intermediate EBRT, RP+EBRT
NR NR NR Intermediate EBRT, BT
8.7 (2.6-46) NR NR High EBRT
NR 42.1 57.9 NR EBRT, RP+EBRT
13 (4.1-97) 80 20 Intermediate EBRT, BT
rate; R, retrospective; P, prosp , not recorded; GS, Gleason score; EBRT, external beam radiotherapy; PBT, proton
ed.
ent characteristics for EBRT
(mo)(range) BCR definit GS % GS (≤7) % GS (≥8) Imaging for relapse Biopsy
(28-150) Phoenix NR NR NR C-PET, MRI Yes (83%)
(31-241) Phoenix 7 64 36 MRI Yes (100%)
7 (23-208) Phoenix 7 NR NR C-PET, MRI, CT Yes (44%)
(9-205) Phoenix NR NR NR C-PET, MRI NR
(26-138) NR NR NR NR C-PET No
(24-216) Phoenix 7 66 34 C-PET, MRI Yes (100%)
5 (29-207) Phoenix NR NR NR C-PET, MRI Yes (80%)
(29-141) Phoenix NR NR NR C-PET/ PSMA-PET, MRI No
6.9-615.5) Phoenix 6 NR NR MRI, C-PET Yes (11%)
NR Phoenix NR NR NR PSMA-PET NR
(54-163.2) Phoenix NR NR NR PSMA-PET Yes (100%)
rate; PSA, prostate specific an m primary treatment to salvage therapy; mo, months; BCR, biochemical recurrence;
















































S, boFirst author/ country Year Design Pts (
Leroy (France) 2017 R 23
Fuller (USA) 2020 P 50
Jereczek-Fossa (Italy) 2018 R 64
Loi (Italy) 2018 R 50
D'Agostino (Italy) 2019 R 23
Pasquier (France) 2019 R 100
Scher (France) 2019 R 42
Cuccia (Italy) 2020 R 24
Matrone (Italy) 2020 R 44
Caroli (Italy) 2020 R 38
Bergamin (Australia) 2020 P 25
BT, brachytherapy; HDR, high dose rate; LDR, low dos
beam treatment; RP, radical prostatectomy.
For PSA, ISUP and GS, the median scores are presen
TABLE 5 | Pre-salvage therapy disease and treatm
First author/ country Year Design TRS
Leroy (France) 2017 R 65
Fuller (USA) 2020 P 98
Jereczek-Fossa (Italy) 2018 R 99
Loi (Italy) 2018 R 7
D'Agostino (Italy) 2019 R 90
Pasquier (France) 2019 R 90
Scher (France) 2019 R 82
Cuccia (Italy) 2020 R 69
Matrone (Italy) 2020 R 60 (
Caroli (Italy) 2020 R
Bergamin (Australia) 2020 P 99.6
BT, brachytherapy; HDR, high dose rate; LDR, low dos
ASTRO, American Society for Radiation Oncology; MRI,









UP GS % GS (≤7) % GS (≥8) T stage %
/3 7 82.5 4.3 T2
R NR NR NR NR
/3 7 NR NR NR
R NR 70 30 NR
R NR NR NR NR
1 6 93 7 NR
/3 7 82 18 NR
3 7 79 21 NR
/3 7a NR NR NR
2 7 100 0 T3
2 7 72 28 T2a
e; Pts, patients; n, number; PSA, prostate specific antigen; NR
ies.
Age (years)(range) PSA (ng/mL)(range) ISUP
70 (58-82) 2.5 (0-11.7) NR
74 (50-89) 3.97 (0.1-48.2) 3
73.2 (52.6-81.7) 3.89 (0.17-51.8) 2/3
76 (62-86) 2.6 (1-30) NR
78 (69-85) 3.2 (1.2-13.5) NR
71.2 (56-86) 4.3 (2.0-38.3) 3
64 (49-77) 3.1 (0.01-23.7) NR
75 (65-89) 1.79 (0.18-10) NR
76 (56-89) 2.6 (2-7.68) 1
75 (71-80) 1.1 (0.82-2.59) NR
72 (62-83) 4.1 (1.1-16.6) NR
; NR, not recorded; GS, Gleason score; TRS, median time fro
ne scan; CT, computed tomography; US, ultrasound; C-PET,





BC (%) Oncologic outcomes
No 18.7 90.8 2-yr bRFS 89%
NR NR 46 (PSA<6)
vs 18
(PSA>6)




55.7 5-yr bRFS 51%, 5-yr OS 92%
Yes (12%) 13 (4-48) NR 2-yr bRFS 74%
Yes (43%) 36 (2-66) 68.5 5-yr OS 90.3%
Yes
(34.5%)
73 (61-140) 45 5-yr bRFS 45%, 5-yr OS 95.5%
Yes
(14.3%)
61 (10-149) 47.6 NR
Yes (53%) 41 (11-76) 67 5-yr CSS 87%
Yes (45%) 52 67.5 5-yr bRFS 65%
Yes
(532%)
52 68 5-yr bRFS 79%
Yes (8%) 21 (1-53) 46 2-yr bRFS 63%, 3-yr bRFS 46%
Yes (74%) 26 (1-60) 79 3-yr bRFS 41.8%
Yes (12%) 31 (13-58) 48 2.5 yr bRFS 51%, mFS 75%, OS
98%





61 (7-150) 67 7-yr RFS 67%
Yes
(26.8%)
48 (25-109) NR 5-yr bRFS 77%, 5-yr OS 70%
Yes (16%) 41.7 (21.8-
185.2)
34 3-yr bRFS 48%, 5-yr bRFS 34%.
LC 98%
No 30 (12-84) 87 3-yr bRFS 83.9%,
5-yr bRFS 41.9%
No 47 (14-75) 72 4-yr bRFS 70%
Yes (57%) 36 NA 5-yr bRFS 38%, 5-yr OS 81%
Yes (29%) 30 (13-65) 87.5 3-yr bRFS 89.5% 3-year CSS
96%
Yes (84%) 86 (2-156) NA 5-yr bRFS 65%, 5-yr CSS 94%,
5-yr OS 96%
NA 108 19 1-yr bRFS 51%, 5-yr bRFS 20%,
5-yr CSS 74%, 5-yr OS 72%
NR 36 (10-45) 71 3-yr bRFS 71%
Yes (90%) 60 (7-164) 68.6 5-yr OS 64%, 5-yr mFS 90%
Yes (34%) 78 (5-139) NR Estimated 10-yr PCaSS 43%,
10-yr OS 34%
NR 54 NR NR
Yes
(93.5%)
75 (1-228) NR 5-yr bRFS 63%, 10-yr bRFS
52%
Yes (43.9) 49 (12-129) 65.6 5-yr bRFS 65.6%, LC 86.6%














































Dose (total dose (Gy)/ dose per
fraction/ number of fractions)
Duration of
treatment
B Lee (USA) 2007 1 21 HDR Ir-192 Whole 36/6/6 7 days
Lyczek (Poland) 2009 1 115 HDR Ir-192 Whole 30 / 10 / 3 9 weeks
Chen (USA) 2013 1 52 HDR Ir-192 Whole 36 / 6 / 6 10 days
Kukielka (Poland) 2014 1 25 HDR with
interstitial
hyperthermia
Ir-192 Whole 37924 63 days
*Yamada (USA) 2014 1 42 HDR Ir-192 Whole 32 / 8 / 4 30 hours
Jiang (Germany) 2016 1 29 HDR Ir-192 Whole 30 / 10 / 3 3 weeks
Lacy (USA) 2016 1 21 HDR Ir-192 Whole 108-144 Gy –
Wojcieszek
(Poland)
2016 1 83 HDR Ir-192 Whole 30 / 10 / 3 28-30 days
Lopez (Spain) 2019 2 75 HDR Ir-192 Whole 32 / 7-10 / 2-4 –
44 LDR NR Whole 145 Gy –
Chitmanee (UK) 2020 1 50 HDR Ir-192 Focal 1 x 19 Gy –
Slevin (UK) 2020 1 43 HDR Ir-192 Focal 1 x 19 Gy –
van Son
(Netherlands)
2020 1 50 HDR (MRI
Guided ultra-
focal)
Ir-192 Ultra-focal 1 x 19 Gy –
Kollmeier (USA) 2017 1 37 LDR 125-I (8%) or
103-Pd (92%)
Whole 125-144 Gy –
61 HDR Ir-192 Whole 32 / 8 / 4 (n=58), 28 / 7 / 4 (n=1)
and 22 / 11 / 2 (n=1)
30 hours
Baumann (USA) 2017 1 33 HDR/LDR 103-Pd (LDR)
and Ir-192
(HDR)
Whole LDR (90-100 Gy) or HDR (30/6/5) NR
Henriquez (Spain) 2014 1 56 HDR/LDR Ir-192/ 125-I Whole HDR: 50.5 / 5.25 / 1-4, LDR: 145 Gy NR
Grado (USA) 1999 1 49 LDR 125-I (76%) or
103-Pd (24%)
Whole 80-180 Gy –
Koutrouvelis (USA) 2003 1 31 LDR 125-I (77%) or
103-Pd (23%)
Whole 100-144 Gy –
Nguyen (USA) 2007 1 25 LDR 125-I Whole 137 Gy –
HK Lee (USA) 2008 1 21 LDR 103-Pd Whole 90 Gy –
Aaronson (USA) 2009 1 24 LDR 125-I or 103-Pd Whole 146 Gy –
Burri (USA) 2010 1 37 LDR 103-Pd (97%) or
125-I (4%)
Whole 110-135 Gy –
Moman
(Netherlands)
2010 1 31 LDR 125-I Whole 145 Gy –
Peters
(Netherlands)
2014 1 20 LDR 125-I Focal 144 Gy –
Vargas (USA) 2014 1 69 LDR 125-I Whole 100 Gy –
Peters
(Netherlands)
2016 2 62 LDR (Whole
Gland)
125-I Whole 145 Gy –
Crook (Canada) 2019 2 92 LDR 125-I (92%) or
103-Pd (8%)
Whole 120-140 Gy –
Smith (USA) 2020 2 108 LDR 125-I (1%) or
103-Pd (99%)
Whole 100 Gy –
Schonle (Germany) 2020 1 82 PDR Ir-192 Whole 60 / 30 / 2 4 weeks
BT, brachytherapy; HDR, high dose rate; LDR, low dose rate; 125-I, Iodine-125; 103-Pd, Palladium-103; Ir-192, Iridium-192; Gy, Gray; ADT, androgen deprivation therapy; mo,
metastasis free survival; RFS, relapse free survival; CSS, cancer specific survival; OS, overall survival.
Yamada (USA) study cohort included in further publication Kollmeier (USA) however specific treatment characteristics and toxicity were not covered in later paper.m
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Frontiers in Oncology | www.frontiersin.org 928 BT studies, 24 included only patients with biopsy-proven local
recurrence. Three of 11 SBRT studies included patients with
histological confirmation of recurrence.
For BT studies, median follow up duration (range) was 47.5
months (13-108) compared with 25.4 months (21-44) for SBRT
studies. The use of ADT with salvage therapy ranged from 8-
100% in the BT study group and 14-61% in the SBRT group.
Oncological Outcomes
For the LDR-BT studies, the median (range) 2-year and 5-year
bRFS rates were 71% (48-89.5%) and 52.5% (20-79%). For the
HDR-BT studies, the median (range) 2-year and 5-year bRFS
rates were 74% (63-89%) and 51% (45-65%). For the SBRT
studies, the median (range) 2-year bRFS for the SBRT group was
54.9% (40-80%). A 5-year estimate of bRFS following SBRT was
only available for one study and was 60% (47). For focal gland
BT, the median (range) 3-year bRFS was 63% (42-71%). For focal
SBRT, the median (range) 3-year bRFS was 69% (58-80%). 3-
year bRFS was presented as 2-year bRFS was not reported by the
majority of these focal RT studies.TOXICITY
A summary of clinician reported acute and late GU and GI
toxicity data for each study is presented in Table 8 (BT) and
Table 9 (SBRT).
In studies that only included LDR-BT, mean (range) grade 3
or higher toxicities were 7.4% (0-14%) (acute GU), 13.6% (0-
30%) (late GU), 6.5% (0-19%) (acute GI) and 6.4% (0-20%) (late
GI). In studies that only included HDR-BT, mean (range) grade
3 or higher toxicities were 2% (0-14%) (acute GU), 7.9% (0-
21.3%) (late GU) and 0.1% (0-0.9%) (late GI). No grade 3 or
higher acute GI toxicity was reported. For the SBRT group, mean
(range) grade 3 or higher toxicities were 1.8% (0-8.7%) (acute
GU), 2.7% (0-8%) (late GU), 0.5% (0-4%) (acute GI) and 0.2%
(0-1.5%) (late GI).
For the focal gland BT group (n=4) (16, 34, 36, 38), the only
grade 3 or higher toxicity reported was late GU toxicity – with a
mean (range) of 4.8% (2-10%). For the focal gland SBRT group
(n=4) (46, 51, 53, 54), mean (range) grade 3 or higher toxicities
were 0.5% (0-2%) (acute GU), 1.5% (0-4%) (late GU) and 1% (0-
4%) (acute GI). No late GI toxicity was reported.
Symptoms of erectile dysfunction were specifically reported
by nine BT studies (32%) and one SBRT study (9%).
Thirteen studies (33.3%) (12 BT and one SBRT study)
included PROMs, with the most common assessment tool used
being the international prostate symptom score (IPSS).DISCUSSION
This systematic review evaluated the most up-to-date evidence for
salvage BT and SBRT and found that both treatment options
provide good biochemical control with acceptable late GU/GI
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TABLE 8 | Toxicity details for BT studies.
GU toxicity Late GI toxicity Erectile Dysfunction PROMS
Grade ≥ 3 Grade ≤ 2 Grade ≥ 3
9.0% 91.0% 2.0% NR Yes (IPSS)
12.0% 3.0% – NR Yes (IPSS)
13.0% 6.0% – NR NR
10.0% 57.0% – Yes Yes (IPSS)
5.0% 35.0% – Yes (80%) Yes (RAND-36, EORTC)
8.7% 7.0% 3.0% NR NR
2.0% 100.0% – Yes (81%) NR
11.0% NR 3.0% Yes (75%) NR
19.0% 51.0% 6.0% NR NR
4.0% NR 4.0% NR Yes (IPSS, IIEF-5)
– 5.0% – NR NR
20.0% NR 20.0% NR NR
5.0% – – Yes (95%) NR
13.0% 13.0% 19.0% NR NR
20.0% 4.0% 2.0% NR NR
2.0% 14.0% – NR NR
21.3% NR NR NR NR
27.3% NR NR NR NR
7.0% NR 4.0% NR Yes (IPSS)
15.7% NR 2.8% Yes (80%) Yes (IPSS, MSEFS)
– – – NR Yes (IPSS)
6.1% 2.4% – NR NR
10.0% 30.0% – Yes (86%) Yes (IPSS)
23.0% NR 4.0% NR NR
30.0% NR 10.0% NR NR
9.0% 100.0% – NR Yes (IPSS)
2.0% 37.0% – Yes (100%) Yes (IPSS, RAND-36)
9.6% 9.6% 9.6% Yes (45.5%) Yes (IPSS)
12.2% 1.7% 0.9% NR NR
rse Events; RTOG, Radiation Therapy Oncology Group; NR, not reported; PROMS, patient recorded outcome
Research and Treatment of Cancer Quality of Life questionnaire; IIEF-5, International Index of Erectile Function


































10First author (country) Toxicity Scale Acute GU toxicity Acute GI toxicity Late
Grade ≤ 2 Grade ≥ 3 Grade ≤ 2 Grade ≥ 3 Grade ≤
Kollmeier (USA) CTCAE v4.0 96.0% – 96.0% – 82.0%
Baumann (USA) CTCAE v4.0 82.0% – 9.0% – 42.0%
Wojcieszek (Poland) CTCAE v4.0 87.0% 1.0% 6.0% – 72.0%
*Yamada (USA) CTCAE v3.0 78.0% – NR NR 86.0%
Peters (Netherlands) CTCAE v4.0 100.0% – 55.0% – 40.0%
Vargas (USA) NR 5.0% 8.7% NR NR 5.0%
Chen (USA) CTCAE v4.0 98.0% 2.0% 100.0% – 98.0%
Burri (USA) CTCAE v3.0 35.0% 11.0% 5.0% NR 35.0%
Moman (Netherlands) CTCAE v3.0 87.0% 3.0% 55.0% – 55.0%
Aaronson (USA) CTCAE v3.0 NR NR NR 3.0% 37.0%
HK Lee (USA) RTOG 29.0% – 5.0% – 29.0%
Nguyen (USA) RTOG NR NR NR NR NR
B Lee (USA) CTCAE v3.0 86.0% 14.0% 14.0% – NR
Koutrouvelis (USA) NR 13.0% 13.0% 13.0% 19.0% 13.0%
Grado (USA) NR NR NR NR NR 10.0%
Slevin (UK) CTCAE v4.0 91.0% – 14.0% – 65.0%
Lopez (Spain) RTOG 33.0% NR NR NR NR
RTOG 33.0% NR NR NR NR
Crook (Canada) CTCAE v3.0 NR 14.0% NR 14.0% NR
Smith (USA) CTCAE v5.0 NR NR NR NR NR
Kukielka (Poland) CTCAE v4.0 96.0% – 12.0% – 41.0%
Schonle (Germany) CTCAE v4.0 15.8% 6.1% 2.4% – 15.8%
Chitmanee (UK) NR 90.0% – 32.0% – 72.0%
Henriquez (Spain) CTCAE v3.0 NR NR NR NR NR
Peters (Netherlands) CTCAE v4.03 NR NR NR NR NR
Jiang (Germany) CTCAE v4.0 100.0% – 100.0% – 90.9%
van Son (Netherlands) CTCAE v4.0 65.0% – 37.0% – 55.0%
Lacy (USA) RTOG 9.6% 9.6% 9.6% 9.6% 9.6%
Lyczek (Poland) RTOG 29.6% 2.6% 7.9% NR 7.0%
- , 0% reported toxicity; NR, not reported; GU, genitourinary; GI, gastrointestinal; CTCAE, Common Terminology Criteria for Adv
measures; IPSS, International prostate symptom score; RAND-36, RAND-36 Health Survey; EORTC, European Organisation fo
questionnaire; MSEFS, Mount Sinai Erectile Function Score.
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evaluated treatments, reported endpoints, duration of follow up
and methods of toxicity assessment (clinician-assessed versus
PROMs). The quality of studies was low and meta-analysis was
therefore not conducted due to the significant bias associated with
these uncontrolled studies. This highlights the need for further
high quality prospective and randomised studies to measure the
efficacy and toxicity associated with salvage irradiation.
Consensus national and international recommendations for
reirradiation are limited. The European Association of Urology
(EAU) guidelines recommend salvage reirradiation using BT or
SBRT for locally recurrent prostate cancer should only be
undertaken in a clinical trial setting (55). American Society for
Radiation Oncology (ASTRO) and National Comprehensive
Cancer Network (NCCN) clinical practice guidelines does not
comment on the use of reirradiation for prostate cancer however
both the European Society of Radiation Oncology (ESTRO) and
American Society of Brachytherapy (ABS) recommendations on
prostate HDR-BT highlight the accumulating evidence for
salvage HDR-BT in local recurrence as showing great promise
(56–58).
There has been increasing interest in the use of salvage
therapies for locally recurrent prostate cancer after primary
radiation, although concerns have been raised regarding the
potential for severe late toxicity (59). Both BT and SBRT, show
durable outcomes in terms of biochemical control with
reasonable reported toxicities in the majority of reviewed
studies. However, inconsistencies in reporting and missing data
preclude accurate comparison between these studies, which are
mainly composed of case series. Longer term efficacy data and
duration of follow up was available for more BT studies than
SBRT but, at short term follow-up, the clinician-reported toxicity
following salvage SBRT appear to be infrequent (60).
Two previous meta-analyses which compared salvage
therapies in recurrent prostate cancer have been conducted,
which included radical prostatectomy, cryotherapy and HIFU
in addition to BT and EBRT (10, 61). The meta-analysis by Valle
et al. (61) reported that recurrence free survival and toxicity rates
were best for salvage radiotherapeutic modalities compared to
other salvage treatments, and BT appeared to offer the best
balance between toxicity and efficacy. For example, the estimated
recurrence free survival at 2 years for BT was 77-79% compared
to 52-72% for cryotherapy, HIFU and salvage radical
prostatectomy. In addition, lower grade 3 or higher GU
toxicity was observed (5-10% versus 20% for BT compared
with other salvage therapies) (61). The quality of the evidence
was not assessed and sub-group and sensitivity analyses to
explore potential impact of clinical heterogeneity were also not
specified in this meta-analysis (61). In addition, it was unclear
how many studies were excluded from the meta-analysis due to
incompatible definitions, outcome measures and follow-up
periods. Interestingly, the 2-year bRFS of SBRT (54.9%)
appeared to be lower than both LDR- and HDR-BT (71% and
74% respectively). A formal comparison between these
modalities is limited by confounding factors, although these
data raise an interesting question as to whether salvage SBRT
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Zhong et al. Prostate Reirradiation Systematic ReviewComparing the SBRT studies to BT remains challenging in
view of the heterogeneous populations and shorter follow-up
available for SBRT with only one study providing 5-yr bRFS data
(although in this study, comparable to outcomes from salvage BT
were reported) (47). No prospective randomised studies exist
which compare BT and SBRT as salvage therapies for locally
recurrent prostate cancer and this is ultimately what is required.
There may be dosimetric advantages with the use of BT
compared with SBRT. A previous planning study in the
primary disease setting concluded that HDR-BT was able to
achieve higher intraprostatic doses and greater sparing of the
rectum than SBRT (62). It is possible that developments in SBRT
planning and delivery might lead to improved outcomes. For
example, the superior soft tissue visualisation and functional
imaging capabilities of MR guided SBRT might permit better
delineation of tumour, greater accuracy of treatment delivery and
offer opportunities for dose escalation (63). Whether this would
translate into a clinical benefit at this point remains uncertain.
There remains considerable interest in salvage SBRT as
evidenced by the fact that 8 of 11 SBRT studies were published
in the last two years.
Based on the studies evaluated in this review, salvage LDR-BT
appeared to have the potential for higher grade 3+ toxicity
compared to HDR-BT (19, 24). In a study which used PROMs,
LDR-BT had a higher peak change in IPSS in the early post-
implant period and a higher peak urinary symptom flare at 12
months compared with HDR-BT, although the majority of these
scores returned to baseline 2-3 years post-treatment (40). There
have been no prospective studies comparing these techniques in
the reirradiation setting. In the primary treatment setting
however prospective and randomised studies have shown
HDR-BT to have better quality of life scores compared to
LDR-BT in the acute post-treatment phase, particularly in the
urinary health domain, which suggests that HDR was better
tolerated (64, 65). Similarly, evidence from registries and
randomised trials of LDR/EBRT combination therapy and
HDR/EBRT combination therapy in the primary disease
setting suggest that LDR/EBRT might be associated with
higher incidence of significant late GU toxicity although no
direct comparison has been performed between the two
treatments (66–68).
Based on the available data, grade 3 or higher GU and GI
toxicity with SBRT was rare, although follow-up beyond 2 years
is limited (9, 45–54). SBRT has the potential to limit the risk of
severe late GU/GI toxicity compared with less conformal EBRT
techniques (69). Careful patient selection remains vital, especially
for those at greater risk of excess toxicity following salvage
therapy. In a recent observational series of salvage SBRT, grade
3+ GU toxicity was disproportionately observed in patients
treated with BT or radical prostatectomy plus salvage RT in
the primary disease setting (47). Furthermore, the use of focal
salvage techniques with BT and SBRT appear to have lower
toxicity rates and comparable bRFS rates however this is limited
to a number of uncontrolled, single-arm case series (16, 34, 36,
38, 46, 51, 53, 54).
Appropriate patient selection for salvage RT treatments is
vital. The European Society for Radiotherapy and OncologyFrontiers in Oncology | www.frontiersin.org 12Advisory Committee on Radiation Oncology Practice (ESTRO
ACROP) recently conducted a Delphi consensus of expert
opinion on patient selection criteria for salvage RT (70).
Selection criteria with high levels of agreement (>80%)
included Eastern Cooperative Oncology Group performance
status of 0-1, satisfactory urinary flow with a known IPSS prior
to salvage and use of PET-CT to exclude metastatic disease and
MRI to define the target. Agreement was reached that
concomitant ADT with salvage RT was unnecessary and that
previous ADT use was not a contraindication to salvage RT. It
was also recommended that the primary RT dose should be taken
into account when considering salvage SBRT. In terms of time
duration between primary RT and salvage RT, although
consensus was not achieved a minimum interval of 2 years
reached major agreement (defined as 65-80% agreement).
The impact on quality of life has not been well assessed in the
salvage radiotherapy setting with only a third of studies in this
systematic review including PROMs. Only one of 11 SBRT
(9.1%) studies included PROMs. Without this information, it is
likely that reported rates of toxicity are underestimated (71).
Assessment of residual toxicity following primary treatment
using validated PROM instruments such as Expanded Prostate
Cancer Index (EPIC) could be an important tool for
identification of patients at risk of significant toxicity from
salvage therapies. Integration of longitudinal PROM
assessment into clinical trials is important to ascertain the
time-dependent nature of toxicity onset/resolution after
treatment (71, 72).
The role of ADT with salvage BT/EBRT remains unclear and
no consensus could be reached during a previous Delphi
consensus (73). The use of ADT with salvage radiation therapy
in the evaluated studies was highly variable (8-100%) and
reporting of ADT duration was incomplete (16, 32, 36, 41, 74).
Several BT studies did not report ADT usage or did not use
neoadjuvant ADT (24, 25, 33). Salvage therapies may delay the
need for ADT, with up to 69% patients remaining free of ADT at
5 years following salvage SBRT (47). Some authors view salvage
BT/SBRT as ADT sparing, which might have the potential to
improve quality of life (75).
A recent study found that only 15% of relapses following
salvage BT were solely in the prostate (36), suggesting most are
likely to be systemic failure therefore accurate and consistent
whole body imaging staging is imperative. The optimal
combination of re-staging imaging following biochemical
failure after primary treatment, and the most clinically relevant
PSA level at which to trigger such imaging, remains uncertain
(76). Despite the poor accuracy of CT and isotope bone
scintigraphy, 21% of studies in this systematic review used
these modalities for restaging and patient selection. It is
possible that some patients in these studies could have had
undiagnosed metastatic disease, and this could be responsible
for some subsequent biochemical failures (75, 77). Less than half
of studies used mpMRI and PET-CT for re-staging prior to
salvage therapy. mpMRI has the potential to be particularly
useful for detecting local recurrence following previous
prostate radiotherapy, although studies evaluating its accuracy
are limited (78). The use of novel imaging modalities such asSeptember 2021 | Volume 11 | Article 681448
Zhong et al. Prostate Reirradiation Systematic ReviewGallium-68 [68Ga] or Fluorine-18 [18F] labelled PSMA PET-CT,
may allow detection of local recurrence at lower PSA levels.
While this could lead to a change in management for patients
identified with recurrent disease, it was only used in 10% of the
studies in this systematic review (79). 68Ga-PSMA PET-CT has
been shown to demonstrate recurrences at prostate-specific
antigen (PSA) levels below the Phoenix definition of
biochemical failure and it allows for both local staging and
exclusion of distant metastatic disease in patients with
biochemical failure (80). The recent proPSMA randomised
study reported that PSMA PET-CT had a greater accuracy
compared to conventional imaging with CT and bone scan in
the primary setting (92% vs 65%) (81). PSMA PET-CT also has
superior performance characteristics for the detection of distant
metastasis in the setting of biochemical failure compared to other
PET tracers (82). Nevertheless, the clinical significance of
detecting and treating small volume local recurrence at low
PSA levels remains uncertain and may risk additional toxicity.
Prospective randomised trials comparing BT and SBRT for
salvage treatment of locally recurrent prostate cancer are
required to determine the efficacy/toxicity of these interventionsSUMMARY OF MAIN FINDINGS
• For the LDR-BT studies, the median (range) 2-year and 5-
year bRFS rates were 71% (48-89.5%) and 52.5% (20-79%).
• For the HDR-BT studies, the median (range) 2-year and 5-
year bRFS rates were 74% (63-89%) and 51% (45-65%).
• For the SBRT studies, the median (range) 2-year bRFS for the
SBRT group was 54.9% (40-80%).
• For LDR-BT, mean (range) grade 3 or higher toxicities were
7.4% (0-14%) (acute GU), 13.6% (0-30%) (late GU), 6.5% (0-
19%) (acute GI) and 6.4% (0-20%) (late GI).
• For HDR-BT, mean (range) grade 3 or higher toxicities were
2% (0-14%) (acute GU), 7.9% (0-21.3%) (late GU) and 0.1%
(0-0.9%) (late GI). No grade 3 or higher acute GI toxicity was
reported.
• For SBRT, mean (range) grade 3 or higher toxicities were
1.8% (0-8.7%) (acute GU), 2.7% (0-8%) (late GU), 0.5% (0-
4%) (acute GI) and 0.2% (0-1.5%) (late GI).
• Only thirteen studies (33.3%) included PROMs, with the most
common assessment tool used being IPSS.LIMITATIONS
The overall quality of evaluated evidence was low. A meta-
analysis was not conducted to quantitatively compare the
studies as the majority of these were non-comparative
retrospective case series with differences in baseline patient
demographics, primary and/or salvage treatments, reported
endpoints reported and use of ADT. This limits the
conclusions that can be drawn about the effectiveness/toxicity
of salvage BT/SBRT. High-quality data from prospective trialsFrontiers in Oncology | www.frontiersin.org 13are still needed to validate the toxicity and long-term clinical
outcomes associated with the salvage treatment of recurrent
prostate cancer using BT or EBRT, following previous RT.CONCLUSIONS
Salvage reirradiation of radiorecurrent prostate cancer using
HDR-BT or SBRT provides similar biochemical control and
acceptable late toxicity. Salvage LDR-BT is associated with
higher late GU/GI toxicity. Challenges exist in comparing BT
and SBRT from the current literature due to inconsistencies in
reporting and missing data. Prospective randomised trials
comparing BT and SBRT and assessing PROMs as well as
cancer control outcomes in this setting are needed.DATA AVAILABILITY STATEMENT
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